OrganOx: A pioneer in organ preservation

Founded in 2008 in Oxford, OrganOx is a UK-based medtech company specializing in innovative solutions for the preservation and optimization of organs intended for transplantation. Leveraging its proprietary technology, the company enables organs to be preserved for longer and helps reduce the risk of rejection. With a growing presence in Europe and North America, OrganOx is steadily establishing itself as a reference player in a rapidly expanding market.

A Company Positioned at the Heart of a High-Growth Market

OrganOx operates in a medical segment driven by structural trends such as the shortage of available organs, the lengthening of waiting lists, and the increasing need to optimize hospital resources. Its proprietary technology, Metra, represents a major competitive advantage, having demonstrated its ability to improve graft viability and increase transplantation success rates. Backed by sustained growth momentum, a base of leading institutional clients, and a promising R&D pipeline, OrganOx is positioned as a key player in the transplantation space with significant international growth potential.

A Clear Commitment to Sustainable and Responsible Healthcare

OrganOx’s mission addresses both a medical and societal challenge: saving more lives while optimizing organ utilization. By extending preservation time and enhancing graft assessment, its technology helps increase the number of organs available and improve equity in access to transplantation. The company is also committed to social responsibility, working closely with research centers and hospitals to improve medical practices and reduce long-term healthcare costs. Its model perfectly illustrates the alignment between positive impact and sustainable performance, in line with institutional investors’ ESG expectations.